Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
Creators: name: Jessen, Frank
name: Spottke, Annika
name: Boecker, Henning
name: Brosseron, Frederic
name: Buerger, Katharina
name: Catak, Cihan
name: Fliessbach, Klaus
name: Franke, Christiana
name: Fuentes, Manuel
name: Heneka, Michael T.
name: Janowitz, Daniel
name: Kilimann, Ingo
name: Laske, Christoph
name: Menne, Felix
name: Nestor, Peter
name: Peters, Oliver
name: Priller, Josef
name: Pross, Verena
name: Ramirez, Alfredo
name: Schneider, Anja
name: Speck, Oliver
name: Spruth, Eike Jakob
name: Teipel, Stefan
name: Vukovich, Ruth
name: Westerteicher, Christine
name: Wiltfang, Jens
name: Wolfsgruber, Steffen
name: Wagner, Michael
name: Duezel, Emrah
Publisher: name: Charité - Universitätsmedizin Berlin
Year: 2018
Subjects: subject: Alzheimer’s disease
subject: Subjective cognitive decline
subject: Mild cognitive impairment
subject: Longitudinal
subject: Cerebrospinal fluid
subject: Beta-amyloid 42
subject: Tau
subject: Apolipoprotein E
subject: Magnetic resonance imaging
subject: Positron emission tomography
subject: 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten

description: Background: Deep phenotyping and longitudinal assessment of predementia at- risk states of Alzheimer’s disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention. Methods: The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics. In addition, individuals with amnestic MCI, mild Alzheimer’s dementia patients, first-degree relatives of patients with Alzheimer’s dementia, and cognitively unimpaired control subjects are studied. The total number of subjects to be enrolled is 1000. Participants receive extensive clinical and neuropsychological assessments, magnetic resonance imaging, positron emission tomography, and biomaterial collection is perfomed. In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets. Results: In comparison with the control group, patients with SCD showed slightly poorer performance on cognitive and functional measures (Alzheimer’s Disease Assessment Scale—cognitive part, Clinical Dementia Rating, Functional Activities Questionnaire), with all mean scores in a range which would be considered unimpaired. APOE4 genotype was enriched in the SCD group in comparison to what would be expected in the population and the frequency was significantly higher in comparison to the control group. CSF Aβ42 was lower in the SCD group in comparison to the control group at a statistical trend with age as a covariate. There were no group differences in Tau or pTau concentrations between the SCD and the control groups. The differences in all measures between the MCI group and the AD group were as expected. Conclusions: The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late- stage preclinical AD. This is indicated by slightly lower performance in a range of measures in SCD in comparison to the control subjects as well as by enriched APOE4 frequency and lower CSF Aβ42 concentration.